MTR

MTR Press Release,
Regards,
Carl.

Meditech says safety trial of anti-cancer drug successful
MELBOURNE, May 16 AAP - Drug development company Meditech
Research Ltd will move towards a Phase II trial of anti-cancer drug
HyDox after the success of the Phase 1 safety trial.
The company said patients with advanced stages of cancer had
been safely administered progressively higher doses of HyDox in the
Phase 1 trial.
"This allows Meditech to begin planning design of its Phase II
clinical trial of HyDox," the company said.
Meditech said results of the Phase I trial were expected to be
available to shareholders by the end of June.
Meditech shares were 1.5 cents higher at 36.5 cents at 1314 AEST
today.
AAP